MX2015009077A - Composicion estable que contiene fingolimod. - Google Patents

Composicion estable que contiene fingolimod.

Info

Publication number
MX2015009077A
MX2015009077A MX2015009077A MX2015009077A MX2015009077A MX 2015009077 A MX2015009077 A MX 2015009077A MX 2015009077 A MX2015009077 A MX 2015009077A MX 2015009077 A MX2015009077 A MX 2015009077A MX 2015009077 A MX2015009077 A MX 2015009077A
Authority
MX
Mexico
Prior art keywords
fingolimod
stable composition
containing stable
ion
pharmaceutically acceptable
Prior art date
Application number
MX2015009077A
Other languages
English (en)
Inventor
Shirish Kulkarni
Sunil Jaiswal
Krishna Sharma
Nitin Bhalachandra Dharmadhikari
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of MX2015009077A publication Critical patent/MX2015009077A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende fingolimod y una resina de intercambio catiónico de ácido débil en la forma de un complejo de intercambio iónico y excipientes farmacéuticamente aceptables.
MX2015009077A 2013-01-15 2014-01-15 Composicion estable que contiene fingolimod. MX2015009077A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN127MU2013 2013-01-15
PCT/IN2014/000030 WO2014111955A1 (en) 2013-01-15 2014-01-15 Fingolimod containing stable composition

Publications (1)

Publication Number Publication Date
MX2015009077A true MX2015009077A (es) 2015-09-10

Family

ID=51209101

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009077A MX2015009077A (es) 2013-01-15 2014-01-15 Composicion estable que contiene fingolimod.

Country Status (5)

Country Link
US (2) US9173948B2 (es)
JP (1) JP2016504413A (es)
MX (1) MX2015009077A (es)
RU (1) RU2015131034A (es)
WO (1) WO2014111955A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016042493A1 (en) 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
RU2639424C2 (ru) * 2015-09-15 2017-12-21 Закрытое Акционерное Общество "Биокад" Твердая пероральная фармацевтическая композиция S1P-агониста или его фармацевтически приемлемой соли, способы ее получения и способы лечения и снижения частоты клинических обострений рассеянного склероза
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
ES2748432T3 (es) * 2006-09-26 2020-03-16 Novartis Ag Composiciones farmacéuticas que comprenden un modulador de S1P
EP2198857A1 (en) * 2008-12-19 2010-06-23 Ratiopharm GmbH Oral dispersible tablet
WO2014013090A2 (en) * 2013-05-06 2014-01-23 Synthon B.V. Formulation comprising amorphous fingolimod

Also Published As

Publication number Publication date
US9173948B2 (en) 2015-11-03
JP2016504413A (ja) 2016-02-12
US20150165057A1 (en) 2015-06-18
US20150366981A1 (en) 2015-12-24
RU2015131034A (ru) 2017-02-01
US9717800B2 (en) 2017-08-01
WO2014111955A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2019013123A (es) Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1).
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
PH12015501753A1 (en) Enhanced stability of novel liquid compositions
MX2020003096A (es) Formulaciones farmaceuticas de un inhibidor de hidroxilasa de hif.
BR112015030268A2 (pt) composição farmacêutica, recipiente, kit, e, método para a preparação de uma composição
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
PH12014502856A1 (en) Solid pharmaceutical preparation containing levothyroxine
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
MX2015016410A (es) Esteres de acidos oligo-hidroxicarboxilicos y uso de los mismos.
PH12015501377A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
MX2015009077A (es) Composicion estable que contiene fingolimod.
NZ715615A (en) Pharmaceutical compositions of ranolazine and dronedarone
IN2013MU01111A (es)
MX2014006201A (es) Formas de dosificaciones solidas de imatinib reconstituidas justo antes de usarse.
HK1219063A1 (zh) 包含透明質酸的藥物組合物用於治療黑椎間盤疾病
MX2015008171A (es) Formulacion que comprende agomelatina amorfa.
IN2013CH04314A (es)
WO2014013090A3 (en) Formulation comprising amorphous fingolimod
IN2014DN07895A (es)
ZA201508860B (en) Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
EA201590776A1 (ru) Пеллеты с пленочным покрытием
IN2013CH03945A (es)